default author photo

Min Yuen Teo

Memorial Sloan Kettering Cancer Center

New York, NY 10065

United States

SCHOLARLY PAPERS

2

DOWNLOADS

149

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Accelerating Drug Development in Hormone-Naïve Prostate Cancer and Changing the Paradigm from Palliation to Cure: The Metacure Phase 2 Randomized Clinical Trial

Number of pages: 29 Posted: 23 Aug 2024
Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute, University of Chicago, Pritzker School of Medicine, University of Chicago Hospitals, Harvard University - Dana-Farber Cancer Institute, Harvard University, Cleveland Clinic, Cleveland Clinic, Harvard University - Dana-Farber Cancer Institute, Harvard University - Brigham and Women's Hospital, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of Chicago, Pritzker School of Medicine, University of Chicago Hospitals, Harvard University, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Cleveland Clinic, Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Robert H. Lurie Comprehensive Cancer Center, University of Chicago, Pritzker School of Medicine, University of Chicago Hospitals, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center
Downloads 116 (613,149)

Abstract:

Loading...

Androgen deprivation therapy, Metastatic prostate cancer, Radical prostatectomy, Stereotactic body radiotherapy

2.

Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

Number of pages: 31 Posted: 10 Mar 2022
Harvard University - Department of Surgery, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center - Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Downloads 33 (1,277,121)

Abstract:

Loading...

Bladder Cancer, Urothelial Carcinoma, ARID1A, FGFR3, cell-free DNA, metastasis, genomic heterogeneity